BACKGROUND: We aimed to clarify the relationship between the maximum tolerated dose and plasma concentration of paclitaxel in Japanese patients with gastric cancer on a weekly paclitaxel administration regimen. METHODS: Thirty-three patients with advanced or recurrent gastric cancer were treated with escalating doses of paclitaxel, administered weekly, along with a fixed dose of 5-fluorouracil or cisplatin. RESULTS: The plasma concentration of paclitaxel remained above 8.5 ng/ml for 24 h after administration. The mean area under the curve increased significantly with escalating dosage levels (R = 0.63; P 0.001). At level 4, patients showing dose-limiting toxicity had a significantly higher plasma paclitaxel concentration than patients without it. CONCLUSION: The weekly administration of paclitaxel, for which a single dose is about one-third of the dose for a tri-weekly treatment regimen, is clinically feasible and appropriate in terms of toxicity and the maintenance of an effective plasma concentration.
BACKGROUND: We aimed to clarify the relationship between the maximum tolerated dose and plasma concentration of paclitaxel in Japanese patients with gastric cancer on a weekly paclitaxel administration regimen. METHODS: Thirty-three patients with advanced or recurrent gastric cancer were treated with escalating doses of paclitaxel, administered weekly, along with a fixed dose of 5-fluorouracil or cisplatin. RESULTS: The plasma concentration of paclitaxel remained above 8.5 ng/ml for 24 h after administration. The mean area under the curve increased significantly with escalating dosage levels (R = 0.63; P 0.001). At level 4, patients showing dose-limiting toxicity had a significantly higher plasma paclitaxel concentration than patients without it. CONCLUSION: The weekly administration of paclitaxel, for which a single dose is about one-third of the dose for a tri-weekly treatment regimen, is clinically feasible and appropriate in terms of toxicity and the maintenance of an effective plasma concentration.
Authors: A M Murad; A Petroianu; R C Guimaraes; B C Aragao; L O Cabral; A O Scalabrini-Neto Journal: Am J Clin Oncol Date: 1999-12 Impact factor: 2.339
Authors: U Vanhoefer; P Rougier; H Wilke; M P Ducreux; A J Lacave; E Van Cutsem; M Planker; J G Santos; P Piedbois; B Paillot; H Bodenstein; H J Schmoll; H Bleiberg; B Nordlinger; M L Couvreur; B Baron; J A Wils Journal: J Clin Oncol Date: 2000-07 Impact factor: 44.544
Authors: C Kollmannsberger; D Quietzsch; C Haag; T Lingenfelser; M Schroeder; J T Hartmann; W Baronius; V Hempel; M Clemens; L Kanz; C Bokemeyer Journal: Br J Cancer Date: 2000-08 Impact factor: 7.640
Authors: Daniel L Hertz; Kelley M Kidwell; Kiran Vangipuram; Feng Li; Manjunath P Pai; Monika Burness; Jennifer J Griggs; Anne F Schott; Catherine Van Poznak; Daniel F Hayes; Ellen M Lavoie Smith; N Lynn Henry Journal: Clin Cancer Res Date: 2018-04-27 Impact factor: 12.531
Authors: Markus Joerger; Stefanie Kraff; Alwin D R Huitema; Gary Feiss; Berta Moritz; Jan H M Schellens; Jos H Beijnen; Ulrich Jaehde Journal: Clin Pharmacokinet Date: 2012-09-01 Impact factor: 6.447
Authors: Charlotte I Stroes; Sandor Schokker; Mohammed Khurshed; Stephanie O van der Woude; Ron Aa Mathôt; Marije Slingerland; Judith de Vos-Geelen; Massimo Zucchetti; Cristina Matteo; Erik van Dijk; Bauke Ylstra; Victor Thijssen; Sarah Derks; Tesfay Godefa; Willemieke Dijksterhuis; Gerben E Breimer; Otto M van Delden; Rob Ha Verhoeven; Sybren L Meijer; Maarten F Bijlsma; Hanneke Wm van Laarhoven Journal: Ther Adv Med Oncol Date: 2022-06-28 Impact factor: 5.485
Authors: M F Kozloff; L P Martin; M Krzakowski; T A Samuel; T A Rado; E Arriola; J De Castro Carpeño; R S Herbst; J Tarazi; S Kim; B Rosbrook; M Tortorici; A J Olszanski; R B Cohen Journal: Br J Cancer Date: 2012-09-18 Impact factor: 7.640